# Table of Contents

3  Introduction
4  Contributors
6  5 Top Take-aways from 2020
7  2020 By the Numbers
10  Funding in 2020: Top 25
12  5 Early-Stage Investors to Know
15  Why We Love New York
16  Building Community
18  Powering through COVID
20  NYC Digital Health 100
22  What Are Your Super Powers?
24  Health Equity
26  Mental Health
29  Healthcare Regulatory: What’s in Store for 2021?
30  Therapeutics & Diagnostics
32  Healthcare SPACs
34  Where Will the Money Flow Next?
36  On the Frontlines
38  The Last Word
39  Team and Methodology

FOLLOW US

---
Last year our lives as New Yorkers changed completely. As the city became the pandemic’s epicenter, offices shut down, schools closed, and healthcare workers became our heroes as they valiantly helped patients battle COVID-19. In the spring and summer, we confronted the issue of systemic racism, which coincided with data showing that the pandemic had impacted Black and Brown communities at far greater numbers than others.

But 2020 was also filled with resiliency, compassion, and collaboration. Many companies in our healthcare ecosystem took action—doubling down, pivoting, accelerating—tackling the immediate challenges facing healthcare as well as their employees.

To better reflect these efforts, we’ve changed the name of the annual publication from Healthcare Venture Capital Report to Healthcare Innovation Report. Because it’s not just about the funding, it’s also about what the entrepreneurs do with that funding—how they’re driving change, improving access, upgrading processes, and impacting lives. This year, more than ever, we needed action and our New York “squad” stepped up and delivered.

As you’ll see throughout the report, the explosion of digital health in New York has been astounding. I remember attending the first-ever Health 2.0 conference in 2007 when digital health meant online support groups, wisdom of the crowd, and blogging. Fourteen years later, technology is embedded in everything we do. Much like digital ad agencies morphed into simply agencies, digital health will become, simply, health. Technology powers everything—it’s what we do with the tech that matters. It’s exhilarating to see the range of ideas and people excited about changing healthcare for the better.

Thank you to our 50+ contributors for their incredible insights. Congratulations to the 100 innovators selected for the 2021 NYC Digital Health 100.

A special shout out to Pfizer for producing a vaccine in record time and making us New York proud.

By the time we publish next year’s report, I hope we will have seen each other again in person at one of NYCHBL’s legendary events.

BUNNY ELLERIN
Co-Founder & CEO,
NYC Health Business Leaders
Many Thanks to Our Contributors

This is our largest group of contributors to date – over 50 entrepreneurs, investors, clinicians, and thought leaders. Thank you for taking the time to share your insights, perspectives, and wisdom with us.

Adrianna Samaniego | Investor  
FEMALE FOUNDERS FUND

Alexander Bisignano | Co-Founder & CEO  
PHOSPHORUS

Alexis Gilroy | Partner  
JONES DAY

Annette Osher, MD | Cardiologist  
OSHER CCPHP

April Koh | Co-Founder & CEO  
SPRING HEALTH

Arabia Mollette, MD | Emergency Medicine Physician  
BROOKDALE UNIVERSITY HOSPITAL

Ashok Subramanian | Co-Founder & CEO  
CENTIVO

Ben Gold, MD | Cardiology Fellow  
MOUNT SINAI HEALTH SYSTEM

Brenton Fargnoli, MD | Partner  
ALLEYCORP

Carolyn Witte | Co-Founder & CEO  
TIA

Carrie SiuButt | CEO  
SIMPLE HEALTH

Charles Boorady | Managing Partner  
HEALTH CATALYST CAPITAL

Ed Gaussen | CEO  
MANTRA HEALTH

Emi Gal | Co-Founder & CEO  
EZRA

Faris Ghawi | CEO  
VYTALIZE HEALTH

Gil Addo | CEO  
RUBICONMD

Gina Bartasi | Founder & CEO  
KINDBODY

Graham Brown | Partner  
LERER HIPPEAU

Jannine Versi | Co-Founder & COO  
ELEKTRA HEALTH

Jean Drouin, MD | CEO  
CLARIFY HEALTH

Jennifer Hawks Bland | CEO  
NEWYORKBIO

Jonas Grossman | President  
CHARDAN

Joseph Habboushe, MD, MBA | Co-Founder & CEO  
MDCALC

Jordan Nof | Co-Founder & Managing Partner  
TUSK VENTURE PARTNERS

Josh DeFonzo | CEO  
LUX HEALTH TECH ACQUISITION CORP.

Maria Gotsch | President & CEO  
PARTNERSHIP FUND FOR NEW YORK CITY

Mark Nathan | Founder & CEO  
ZIPARI

Matt McCambridge | Co-Founder & CEO  
EDEN HEALTH
CONTRIBUTORS CONTINUED >

Matthew Price | Co-Founder & COO
PHOSPLATIN THERAPEUTICS

Maureen Bennett | Partner
JONES DAY

Michael Botta | Co-Founder
SESAME

Michael Cunnion | CEO
REMEDY HEALTH MEDIA

Michael Meng | CEO
STELLAR HEALTH

Misti Ushio, PhD | CEO
TARA BIOSYSTEMS

Nate Maslak | Co-Founder & CEO
RIBBON HEALTH

Nicole Brown, MD, MPH | Founder & Chief Health Officer
STRONG CHILDREN WELLNESS

Nimi Katragadda | Partner
BOXGROUP

Rajiv Shukla | Chairman & CEO
ALPHA HEALTHCARE ACQUISITION CORP.

Ravi N. Shah, MD, MBA | Founding Director
COLUMBIA MIND VENTURES

Ray Lorenzoni, MD | Fellow, Pediatric Cardiology
CHILDREN’S HOSPITAL AT MONTEFIORE

Reena Pande, MD | Chief Medical Officer
ABLETO

Rick Heitzmann | Partner
FIRSTMARK CAPITAL

Robert Accordino, MD, MSc | Chief Mental Health Officer
QUARTET

Robert Fields, MD | SVP & Chief Medical Officer of Population Health
MOUNT SINAI HEALTH SYSTEM

Roshini Malaney, DO | Cardiologist, Staten Island University Hospital
NORTHWELL HEALTH

Ryan Darnell | Managing Partner
MAX VENTURES

Sarah Urke, PT | Acute Care Physical Therapist
NEW YORK-PRESBYTERIAN

Sherman Leung | Medical Student, Icahn School of Medicine at Mount Sinai and Associate
ALLEYCORP

Sloan Gaon | CEO
PULSEPOINT

Stacey Seltzer | Partner
AISLING CAPITAL

Steven Gutentag | Co-Founder & CEO
THIRTY MADISON

Suzette Brown, MD, MPH | Founder & COO
STRONG CHILDREN WELLNESS

Toyin Ajayi, MD | Co-Founder & Chief Health Officer
CITYBLOCK HEALTH

Violeta Michel, RN | Pediatric Nurse, Navajo Nation
INDIAN HEALTH SERVICE

Viral Patel, MD | Founder & CEO
RADISH HEALTH
The funding never stopped.
When the pandemic hit, many of us thought it would have a negative impact on funding—instead there was a 40% bump in funding over 2019—increasing from $2.2B to $3.6B! Digital health was the biggest recipient garnering 69% of the dollars. The rounds got substantially larger: in 2019, only one company (Oscar) raised over $100M; in 2020, Oscar was joined by four more: Cityblock Health, Ro, Cedar and Medly. Another interesting finding: seven of the Top 25 companies raised at least two rounds during the year.

Virtual care took center stage.
Investors poured $1.3B (about 35% of total funding) into virtual care, a reflection of its starring role during the pandemic. Telehealth has been around for decades, but in 2020, millions of patients experienced a video visit for the first time and tens of thousands of once-resistant providers became converts. While it took a pandemic to prod both groups to test it out, regulatory changes to payments and licensing closed the deal. Learn more about what’s ahead on the regulatory front on page 29.

Mental health came out of the shadows.
Mental health has been called the shadow pandemic of 2020 because the levels of depression, anxiety and stress skyrocketed during COVID. As a result, new approaches to mental health treatment have blossomed and become more widely adopted. New York is at the heart of this movement and is quickly becoming the center of digital mental health. Investors put $200M (about 5% of total funding) into this vertical and we expect this area to expand. Learn more about the mental health start-ups driving this growth on page 26.

Health Equity grabbed our attention.
New York’s Black and Brown communities were disproportionately affected by coronavirus, highlighting disparities in care. A number of New York companies are trying to address the imbalance, most notably Cityblock which took in $214M in new funding. Discover more about the issues related to equity and potential solutions necessary to close the gaps on page 24.

Therapeutics & Diagnostics hit the front page.
PCR testing is the new normal, and mRNA technology has become a frequent topic of discussion (at least among this crowd). New York life science companies of all sizes played an active role in addressing COVID-19, most notably Pfizer, but smaller start-ups got in on the action, too. Take a closer look at a few of the players on page 30.
We’ve been tracking New York health and life sciences funding for four years—and the growth has been substantial. In 2020, investment reached an all-time high, and was a 40% increase over 2019.
FUNDING BY SECTOR: 2020 VS. 2019

- **Digital/TECH-ENABLED**
  - 2020: 69% (2,491M)
  - 2019: 52% (1,352M)

- **Life Sciences**
  - 2020: 24% (851M)
  - 2019: 42% (1,092M)

- **Diagnostics**
  - 2020: 7% (269M)
  - 2019: 6% (156M)

FUNDING BY DIGITAL SUB-SECTOR

- **Virtual Care**: 52%
- **Insurance & Pharmacy**: 22%
- **Patient Engagement**: 13%
- **Data & Platforms**: 13%
Early stage includes pre-seed, seed and Series A. Late stage includes Series B and beyond.

2020 BY THE NUMBERS

FUNDING BY STAGE: 2020 VS. 2019

2020

- 73% Late Stage
- 27% Early Stage

2019

- 53% Late Stage
- 47% Early Stage

Early stage includes pre-seed, seed and Series A. Late stage includes Series B and beyond.

MERGERS & ACQUISITIONS

WE ENDED 2020 WITH A MAJORITY RECAPITALIZATION BY THOMA BRAVO and the simultaneous acquisition of HealthX. With the new capital, we’ll be able to add many product enhancements and continue to build a world-class service organization. The HealthX acquisition allows us to bring Zipari’s CX Platform and market-leading products to an additional 170 customers. It’s been an incredible ride from a start-up six years ago to a valuation of over $500 million today...and I feel like we’re still just getting started on our mission to help health plans be more consumer-centric.

MARK NATHAN
Founder & CEO, Zipari

<table>
<thead>
<tr>
<th>Company</th>
<th>Acquired by</th>
<th>Amount (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>care/of</td>
<td>Bayer</td>
<td>$225</td>
</tr>
<tr>
<td>cohero health</td>
<td>AptarGroup</td>
<td>Undisclosed</td>
</tr>
<tr>
<td>doctor.com</td>
<td>Press Ganey Associates</td>
<td>Undisclosed</td>
</tr>
<tr>
<td>Prevail</td>
<td>Lilly</td>
<td>$1,040</td>
</tr>
<tr>
<td>Progenics</td>
<td>Lantheus Medical Imaging</td>
<td>$419</td>
</tr>
<tr>
<td>Stemline</td>
<td>The Menarini Group (Italy)</td>
<td>$677</td>
</tr>
<tr>
<td>zipari</td>
<td>Thoma Bravo</td>
<td>$500</td>
</tr>
<tr>
<td>zipdrug</td>
<td>IngenioRx</td>
<td>Undisclosed</td>
</tr>
</tbody>
</table>
## FUNDING IN 2020

### Top 25

* 7 companies raised multiple rounds during 2020. The Funding number reflects total raised during the year.

<table>
<thead>
<tr>
<th>No.</th>
<th>Company</th>
<th>Description</th>
<th>Funding (M)</th>
<th>Stage</th>
<th>Select Investors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Oscar</td>
<td>Health insurance company using technology, design, and data to humanize health care.</td>
<td>$365*</td>
<td>Late stage</td>
<td>Tiger Global Management, Dragoneer, Baillie Gifford, Coatue, Founders Fund, Khosla</td>
</tr>
<tr>
<td>2</td>
<td>Cityblock</td>
<td>Personalized primary care, behavioral health care, and social services for underserved urban populations.</td>
<td>$214*</td>
<td>Late stage</td>
<td>Catalyst, Thrive Capital, Sidewalk Labs, Town Hall Ventures, Maverick Ventures, Redpoint Ventures</td>
</tr>
<tr>
<td>3</td>
<td>RO</td>
<td>&quot;The patient company&quot; offering 3 digital health clinics: Roman (men), Rory (women), and Zero (smoking cessation).</td>
<td>$200</td>
<td>Late stage</td>
<td>General Catalyst, FirstMark Capital, BoxGroup, 3L Capital, Tusk Venture Partners, SignalFire, Torch Capital</td>
</tr>
<tr>
<td>4</td>
<td>Neurogene</td>
<td>Biotech developing genetic medicines for those affected by rare, devastating neurological diseases.</td>
<td>$115</td>
<td>Late stage</td>
<td>Cormorant Asset Management, EcoR1 Capital, Samsara BioCapital, Redmile Group</td>
</tr>
<tr>
<td>5</td>
<td>Kallyope</td>
<td>Biotech dedicated to unlocking the therapeutic potential of the gut-brain axis.</td>
<td>$112</td>
<td>Late stage</td>
<td>Alexandria Venture Investments, Lux Capital, Polaris Partners, Casdin Capital, Two Sigma Ventures</td>
</tr>
<tr>
<td>6</td>
<td>NeoGene</td>
<td>Biotech developing next-generation, fully personalized engineered T cells therapies for broad spectrum of cancers.</td>
<td>$110</td>
<td>Early stage</td>
<td>EcoR1 Capital, Jeito Capital, Syncona, Vida Ventures, TPG</td>
</tr>
<tr>
<td>7</td>
<td>Cedar</td>
<td>Patient payment and engagement platform for hospitals, health systems and medical groups.</td>
<td>$102</td>
<td>Late stage</td>
<td>Andreessen Horowitz (a16z), Kaiser Permanente Ventures, Kinnevik, Thrive Capital, Lakestar, Founders Fund</td>
</tr>
<tr>
<td>8</td>
<td>Flame Biosciences</td>
<td>Biotech addressing unmet needs in diseases linked to chronic inflammation including cancer, cardiovascular disease and arthritis.</td>
<td>$100</td>
<td>Late stage</td>
<td>Rock Springs Capital, T. Rowe Price Associates, Cormorant Asset Management LP, Janus Henderson Investors</td>
</tr>
<tr>
<td>8</td>
<td>Medly</td>
<td>Full-service, digital pharmacy offering free same-day prescription delivery.</td>
<td>$100</td>
<td>Late stage</td>
<td>Volition Capital, Greycroft, Horsley Bridge, Lerer Hippeau</td>
</tr>
<tr>
<td>10</td>
<td>Spring Health</td>
<td>Comprehensive behavioral health solution for employers.</td>
<td>$98*</td>
<td>Early and Late stages</td>
<td>Tiger Global, Northzone, Operator Partners, GingerBread Capital, Equinox Ventures, Able Partners</td>
</tr>
<tr>
<td>10</td>
<td>Elevation Oncology</td>
<td>Precision medicine biotech developing drugs to inhibit specific alterations identified via genomic testing.</td>
<td>$98*</td>
<td>Early and Late stages</td>
<td>venBio Partners, Cormorant Asset Management, Aisling Capital, Samsara Biocapital, Janus Henderson</td>
</tr>
<tr>
<td>No.</td>
<td>Company</td>
<td>Description</td>
<td>Funding (M)</td>
<td>Stage</td>
<td>Select Investors</td>
</tr>
<tr>
<td>-----</td>
<td>----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------</td>
<td>------------------</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>Digital care covering primary care, anxiety and depression.</td>
<td>$90*</td>
<td>Late stage</td>
<td>Valor Equity Partners, Marcy Venture Partners, 14W, Mangrove Capital Partners, Lerer Hippeau, Primary Venture Partners</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td>Home lab testing and clinical services.</td>
<td>$71</td>
<td>Late stage</td>
<td>Illumina Ventures, HLM Venture Partners, Deerfield Management, Transformation Capital, Optum Ventures</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td>On-demand, live insights to accelerate discovery and development of therapies.</td>
<td>$71*</td>
<td>Early and Late stages</td>
<td>IVP, Menlo Ventures, Lux Capital, Transformation Capital, Lead Edge Capital</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>Next generation CRISPR company.</td>
<td>$61</td>
<td>Late stage</td>
<td>AnGes, OrbiMed, Takeda Ventures</td>
</tr>
<tr>
<td>16</td>
<td></td>
<td>Teeth alignment technology.</td>
<td>$54</td>
<td>Early stage</td>
<td>Greycroft Partners, Gaingels Syndicate, Bessemer Venture Partners, Redesign Health, Riverpark Ventures</td>
</tr>
<tr>
<td>17</td>
<td></td>
<td>Mobile-health platform and device for self physical examination, and remote diagnosis.</td>
<td>$50</td>
<td>Late stage</td>
<td>Qualcomm Ventures, West Fountain Global Fund, Insight Partners, Olive Tree Ventures</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>Virtual care and treatments for chronic conditions: Keeps (hair loss), Cove (migraine) and Evens (acid reflux).</td>
<td>$47</td>
<td>Late stage</td>
<td>Polaris Partners, Gaingels Syndicate, J&amp;J Innovation, Maveron, Northzone Ventures</td>
</tr>
<tr>
<td>19</td>
<td></td>
<td>On-demand healthcare and modern family benefits for women and families.</td>
<td>$45</td>
<td>Late stage</td>
<td>GV, Redpoint Ventures, Juxtapose, Zigg Capital, Tusk Venture Partners, Tiger Global Management</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>Dental clinic intended to improve dental visit and wellness experience.</td>
<td>$37</td>
<td>Late stage</td>
<td>Vertical Venture Partners, Health Velocity Capital, HealthWorx, BCBS of NJ</td>
</tr>
<tr>
<td>21</td>
<td></td>
<td>Products for health insurance plans to improve consumer digital experience.</td>
<td>$36.5*</td>
<td>Late stage</td>
<td>Bayer, Brighter Capital, Innova Capital Partners, FJ Labs, RRE Ventures, BoxGroup</td>
</tr>
<tr>
<td>22</td>
<td></td>
<td>Mobile computing and data science to transform the lives of people with diabetes.</td>
<td>$35</td>
<td>Late stage</td>
<td>B Capital Group, Define Ventures, HarbourVest, Nassau Street Ventures, Bain Capital Ventures, F-Prime Capital Partners</td>
</tr>
<tr>
<td>23</td>
<td></td>
<td>Digital health plan for self-funded employers.</td>
<td>$34</td>
<td>Late stage</td>
<td>Health Catalyst Capital, Horizon BCBS of NJ, Goodwater Capital, Three Fields Capital, Lux Capital</td>
</tr>
<tr>
<td>24</td>
<td></td>
<td>Virtual care companion that provides a personalized, connected care experience.</td>
<td>$33</td>
<td>Late stage</td>
<td>Perceptive Advisors, RRE, GV, Freemark Capital, Rock Springs Capital</td>
</tr>
<tr>
<td>25</td>
<td></td>
<td>Fertility, gynecology, and wellness services in modern, tech-enabled clinics.</td>
<td>$32</td>
<td>Late stage</td>
<td></td>
</tr>
</tbody>
</table>
5 EARLY-STAGE

Investors to Know

Visionaries see potential and take risks—they’re the lifeblood of start-ups. Even during a difficult year, early-stage investors have continued to find, fund and incubate some of healthcare’s most exciting companies. Meet five investors making an impact in New York’s venture community.

**Graham Brown**
Partner, Lerer Hippeau

**NY healthcare investments:**
Heartbeat Health, K Health, Klara, Medly Pharmacy, Monument, Opentrons, Oscar, Thrive Global

**Lerer Hippeau**

**Where should healthcare entrepreneurs focus?**
There are two big challenges for healthcare start-ups to tackle. First: How do you keep a healthy population from becoming sick? Second: How do you manage chronic care conditions more efficiently, knowing they generate 80-90% of total healthcare costs? There’s plenty of room for innovation in both areas. Prevention is growing—AI will enable better early detection and diagnosis. Technology can make a major impact in the chronic population with telehealth, pharmacy, remote patient monitoring and efficiency of payments.

**Give us an example from your portfolio.**
Managing medications for your entire life is complex and involves addressing multiple conditions. Medly offers a fundamentally better pharmacy experience by using data more effectively and enabling more personalized plans. Plus they deliver, eliminating the need to visit a brick-and-mortar store. We think Medly is going to be one of the leaders in managing chronic conditions and specialty medicine.

**What impact did COVID have on the space?**
Digital penetration and telehealth have clearly accelerated across the board. That whole world has been pulled forward very rapidly, with an acceleration in adoption and TAM that has exploded. In the long run, though, regulation will also be a big factor in how these trends play out. What happens with reimbursements across the board going forward is very important, especially for telehealth. Cross-state licensing is another unknown. Some restrictions were loosened due to COVID, but we don’t know if those will come back.

**Why healthcare?**
Initially we were less focused as a fund on healthcare because it seemed specialized. Our deep friendships and relationships led us to our first healthcare investments: Flatiron Health and PillPack. Now about 25% of the fund’s focus is healthcare, and much more as a percentage of mind share. As a generalist investor, I love the deeply mission oriented nature of healthcare companies and we’re excited to continue invest in companies that help unlock better healthcare access for all.

**Advice for founders pitching you?**
Make it a conversation and articulate the pain point clearly. A concept that we like is “founder/market fit.” Why are you uniquely positioned to tackle this problem? And why did you choose it? How do you see the market differently than others? Why are you going to spend the next 10 years focused on this? What’s your unfair advantage? Those are some of the “how” and “why” questions that we find most compelling in a pitch.

**Nimi Katragadda**
Partner, BoxGroup

**NY healthcare investments:**
Alma, Blink Health, Clover, Garner Health, K Health, Level, Maven Clinic, Oscar, Ribbon Health, Ro, Tomorrow Health

**BoxGroup**

**Why early?**
I think it’s important to be comfortable with what early stage really means—more questions than answers, more vision than product, more ideas than data—and to me it’s the most personally gratifying stage because investors and founders are able to build a really unique relationship (ideally a trusted friendship) by being there from the beginning. We love meeting founders early, even when it’s just people and an idea. We’ve been very consistent in our strategy, which is laser-focused on the early stage.

**Why healthcare?**
Initially we were less focused as a fund on healthcare because it seemed specialized. Our deep friendships and relationships led us to our first healthcare investments: Flatiron Health and PillPack. Now about 25% of the fund’s focus is healthcare, and much more as a percentage of mind share. As a generalist investor, I love the deeply mission oriented nature of healthcare companies and we’re excited to continue invest in companies that help unlock better healthcare access for all.
What should we know about AlleyCorp?
AlleyCorp founds and funds early-stage companies in New York. Founded by long-time entrepreneur, Kevin Ryan, AlleyCorp is unique in structure—we do not have LPs, we often launch companies as co-founders, we gravitate toward investing in first-time founders, and we focus on NYC. Some of the later stage New York companies AlleyCorp has originated include MongoDB, Gilt, BusinessInsider, Zola, and Nomad Health, and we continue to co-found new companies each year.

What investments did you make in 2020?
Although AlleyCorp is industry-agnostic, we placed a much greater emphasis on healthcare in 2020 than in years past. Within healthcare, we made 10 early-stage investments in 2020 in digital health broadly, with a specific focus around value-based care delivery, digital therapeutics, and data infrastructure. These investments ranged from $1M-$2M, the majority were in NYC, and a few were incubations which we started from scratch.

Why the laser focus on NYC?
A core part of AlleyCorp’s mission since its founding over a decade ago has been to grow entrepreneurship in NYC. The diversity of talent, breadth of industry representation, and strength of creative thinking here is unrivaled. We’ve developed a robust ecosystem to support first-time founders and early-stage company growth in NYC and continue to be very excited about the future of innovation here.

What is your fund’s philosophy?
We believe in female founders and have created a portfolio of 100% female founders. Today women account for less than 2% of venture financing, but we know there will be many billion-dollar companies built by women.

And why healthcare?
We’re generalists but have a thematic approach: B2B, healthcare, fintech, and seed stage. We were early in seeing that women’s health should not be described as a niche area. We invested in Maven Clinic and became aware of the critical need for specific solutions in women’s health. After Maven Clinic, we were early investors in other category-defining health companies such as Shine (wellness), Real (mental health) and Oula (maternal health).

Tell us more about Oula.
Oula is a modern birthing clinic in Brooklyn using a collaborative approach. Eighty percent of births in the US are low-risk and don’t need to be in a hospital. We are also paying attention to the growing disparities in Black and Latino communities. When you look at outcomes for Black women, the maternal mortality rate is high. Oula is looking at ways to use technologies to connect culturally savvy clinicians with underserved populations.
What differentiates Tusk?
We sit at the nexus of technology, politics, and regulation. From our point of view, many of healthcare’s problems stem from misaligned incentives resulting from antiquated regulations and reimbursement rates. So we focus on investing in companies that are operating in highly regulated markets or creating new business models where no regulatory frameworks exist today.

An example of a company breaking the mold?
Ro, because it’s more than just a DTC product company—it’s a vertically integrated new type of healthcare system. Though they started with conditions like E.D. (erectile dysfunction) and hair loss, they are quickly moving into managing chronic conditions like diabetes and thyroid issues. Ro is using telehealth and other technologies to manage patients more efficiently within a safer and more convenient environment.

What about health disparities?
Technology’s largest benefit to the market often is transparency. Zip code by zip code you can see what COVID’s infection rates have been. It’s apparent that this has been a tale of two pandemics—the parts of the population that need our help the most are the least likely to get it. Those are the next problems that need to be solved, and we’re ready to invest in meaningful solutions.
Why We ❤️ New York

New York endured a great deal of loss during 2020. This included the death of Milton Glaser, the iconic designer, who created the instantly recognizable I Love New York logo. Here are just a few reasons why our community will continue to build, support, and invest in New York for years to come.

**AS A COMPANY, WE COULDN’T BE MORE LONG ON NEW YORK.** Our name stems from the first company my roommate and I operated out of our apartment, which was on the corner of 30th and Madison.

**STEVEN GUTENTAG**
Co-Founder & CEO, Thirty Madison

**NYC IS THE LARGEST HEALTHCARE MARKET** in the US and has been the most active metro area for digital health investment in 2020. We have the investment dollars, infrastructure and diversity of talent to build the leading digital health ecosystem. We’re excited about all the activity right in our backyard.

**GRAHAM BROWN**
Partner, Lerer Hippeau

**NEW YORK CONTINUES TO BE AN EXCEPTIONAL PLACE** for innovation—with the opening of significant amounts of new laboratory space as well as the emergence of new funds dedicated to the life sciences, we expect the entrepreneurial wave to continue in a significant fashion.

**JENNIFER HAWKS BLAND**
CEO, NewYorkBIO

**AS A FOREIGNER, I CHOSE TO BUILD MANTRA IN NYC** for its pool of tech and healthcare talent, proximity to some of the largest healthcare players in the US, and access to capital.

**ED GAUSSEN**
CEO, Mantra Health

**NEW YORK IS STILL THE BEST CITY IN THE WORLD TO MOVE FOR YOUNG PEOPLE**—the talent across all industries is outstanding. It makes sense that technology and e-commerce have come together with healthcare to produce great companies. We have a range of NYC companies—Ezra, Ro, Klara, Parsley Health, Hubble—and will be long on this sector and location.

**RICK HEITZMANN**
Partner, FirstMark Capital

**MDCALC BEGAN AS A SMALL PASSION PROJECT** and has grown into the most broadly used medical reference for practical evidence-based tools. New York’s incredible healthcare community—and the relationships we’ve built—have allowed us to evolve in a way that wouldn’t be possible in any other city.

**JOSEPH HABBOUSHE, MD, MBA**
Co-Founder & CEO, MDCalc
Building Community

When we founded NYCHBL in 2009, our goal was to build a healthcare ecosystem in New York. A decade – and pandemic – later, that ecosystem has become a community that supports, partners and works together to drive success for its members. Collaboration is truly King…and Queen.

ONE OF THE CHALLENGES start-ups have is getting on the radar of larger companies. We launched PulsePoint Data Lab to make it easier for health data start-ups to build, launch, and scale. Our goal is to help these innovators with resources like platform access, commercial insights, business skills, legal counsel, and network connections. We’re creating an environment to support these companies in achieving the better health outcomes that we all talk about.

SLOAN GAON
CEO, PulsePoint

A COMMUNITY OF FEMALE FOUNDERS is emerging in New York as well as a growing number of start-ups focusing on women’s health. It’s inspiring to see incumbent Kate Ryder of Maven Clinic so willing to connect with other female founders from Oula and Helania, who are also building women’s health tech start-ups.

ADRIANNA SAMANIEGO
Investor, Female Founders Fund

STELLAR HEALTH BRINGS PAYORS AND PROVIDERS together to deliver value-based care. In 2020, we collaborated with both Elderplan and Rayn IPA to improve value-based delivery across NYC. Most recently, we partnered with Excelsior Integrated Medical Group in Lower Manhattan to further improve the delivery system and overall patient experience. New York has been a great market for us.

MICHAEL MENG
CEO, Stellar Health
NEW YORK IS FULL OF INNOVATIVE, MISSION-DRIVEN companies, and we are honored to partner with several. These include Ro, where we power the “find in-person care” search; Bennie, where we’ve integrated into their employee benefit navigation system; and Particle Health, where we make it easier for health systems and health plans to comply with incoming API regulations.

NATE MASLAK
Co-Founder & CEO,
Ribbon Health

WE UNDERSTAND HOW DIFFICULT IT IS for digital health solutions to lock in a pilot. We’ve developed a tight process under Vytalize Innovation Labs that can deploy solutions within weeks. We take pride in the speed with which we’re able to identify, partner, and execute on an elegant solution that advances value-based care.

FARIS GHAWI
CEO, Vytalize Health

WE LAUNCHED THE MDCALC $1M AD GRANTS PROGRAM to recognize the extraordinary efforts of those supporting clinicians caring for COVID-19 patients. We selected four New York-based companies whose work aligns with our core mission to support providers and improve healthcare: Bluestream Health, Labfinder, Yosi Health, and Vesta Healthcare.

JOSEPH HABBOUSHE, MD, MBA
Co-Founder & CEO, MDCalc

ELEKTRA’S MISSION IS TO SMASH THE MENOPAUSE TABOO. We work with mission-aligned partners to raise awareness. To celebrate World Menopause Month, we partnered with arfa’s State of—a DTC menopause skincare brand—to take over menopause.com. The site was featured on the Today Show!

JANNINE VERSI
Co-Founder & COO,
Elektra Health

WE UNDERSTAND HOW DIFFICULT IT IS for digital health solutions to lock in a pilot. We’ve developed a tight process under Vytalize Innovation Labs that can deploy solutions within weeks. We take pride in the speed with which we’re able to identify, partner, and execute on an elegant solution that advances value-based care.

FARIS GHAWI
CEO, Vytalize Health

WE LAUNCHED THE MDCALC $1M AD GRANTS PROGRAM to recognize the extraordinary efforts of those supporting clinicians caring for COVID-19 patients. We selected four New York-based companies whose work aligns with our core mission to support providers and improve healthcare: Bluestream Health, Labfinder, Yosi Health, and Vesta Healthcare.

JOSEPH HABBOUSHE, MD, MBA
Co-Founder & CEO, MDCalc

NATE MASLAK
Co-Founder & CEO,
Ribbon Health

JANNINE VERSI
Co-Founder & COO,
Elektra Health
Powering Through COVID

Resiliency is the ability to not just survive, but to actually thrive in the face of adversity. During the COVID crisis, these leaders embodied that characteristic in the ways they responded and innovated, pivoting and expanding to meet the needs of their customers — and their own employees.

WE LAUNCHED IN APRIL, at the peak of the first wave of COVID-19. We had to pivot our care delivery immediately, using a range of technologies such as mobile pre-visit registration and text messaging platforms to digitally screen our patients. We saw a dramatic spike in psychosocial needs such as food insecurity, financial hardship, depression, and anxiety. We worked closely with our community partners to ensure that patients were connected to services and supports.

SUZETTE BROWN, MD, MPH
Founder & COO, Strong Children Wellness

WE PRIORITIZED HEALTH AND SAFETY FOR OUR TEAM—not just physical health, but mental health too. To stay connected, we kicked off a ton of events including morning meditation, daily planking, and trivia nights. The pandemic created a bit of a silver lining in that everybody was home and navigating this difficult moment together, even when apart. People showed up bringing their whole selves to work, not just their work selves. And that’s how it should be.

MICHAEL CUNNION
CEO, Remedy Health Media

OUR BUSINESS WAS BUILT FOR THIS MOMENT—we just thought this moment was going to happen 5 or 10 years from now. Millions of people who had never experienced telemedicine were introduced to it for the first time, creating extreme demand for online healthcare visits. We worked to make sure we had the infrastructure in place to scale while still delivering an exceptional, personalized experience.

STEVEN GUTENTAG
Co-Founder & CEO, Thirty Madison

OUR CORE BUSINESS IS genomics-as-a-service, but we know PCR testing well. When COVID struck, we responded quickly. We developed a clinical study to test an at-home saliva test for COVID-19, rapidly recruited patients and received FDA approval (Emergency Use Authorization) in June. It was a sprint but a great decision that opened up new ways to work with employers and individuals. The test was even featured on Dr. Oz.

ALEXANDER BISIGNANO
Co-Founder & CEO, Phosphorus

WE LAUNCHED IN APRIL, at the peak of the first wave of COVID-19. We had to pivot our care delivery immediately, using a range of technologies such as mobile pre-visit registration and text messaging platforms to digitally screen our patients. We saw a dramatic spike in psychosocial needs such as food insecurity, financial hardship, depression, and anxiety. We worked closely with our community partners to ensure that patients were connected to services and supports.

SUZETTE BROWN, MD, MPH
Founder & COO, Strong Children Wellness
I had only been CEO for two weeks when the pandemic forced us to work from home in early March. My first priority was the health and safety of my employees, but as their new leader I also had to earn their trust. I sent every employee a handwritten card letting them know I was thinking about them and encouraging them to take care of their own mental health during this unprecedented time. Almost one year later, we saw employee engagement increase and virtually no attrition.

Carrie Siubutt
CEO, Simple Health

To help our staff stay both physically and mentally healthy, we embedded one of our clinicians on the People team to focus specifically on our own employees. We made changes such as more flexible scheduling, additional vacation time, meeting-free days, and expanded mental health benefits and benefits for parents and guardians of young children.

Robert Accordino, MD, MSC
Chief Mental Health Officer, Quartet

Telemedicine presented an entirely new landscape for the vast majority of physicians. We built our own video visit platform from the ground up and began onboarding and credentialing providers across all 50 states, and we did it for free to help the clinicians in a time of need.

Michael Botta
Co-Founder, Sesame
# NYC Digital Health 100

## Well Being & Care Delivery

### INSURANCE & HEALTH BENEFITS
- Blink Health
- Capital Rx
- Capsule
- Centivo
- Medly
- Nava
- Oscar
- Truveris

### MENTAL HEALTH
- AbleTo
- Alma
- Happify Health
- Headway
- Kaden
- Monument
- Quartet
- Spring Health
- Talkspace
- Tempest
- Valera Health

### WOMEN’S HEALTH
- Extend Fertility
- Kindbody
- Mavin
- Shine
- SimpleHealth
- Tia

### PATIENT ENGAGEMENT
- Cedar
- CipherHealth
- Cohera Health
- Datacubed Health
- Eloovee
- MassivBD
- Noom
- Rightway
- Risalto
- Welth
- Zipari

### VIRTUAL CARE & COORDINATION
- Cecelia Health
- Cityblock
- Cureatr
- Eden Health
- Efforce
- Fruit Street
- Galileo
- Healthify
- Heartbeat
- Kaia Health
- Maven Care
- One Drop
- Pager
- Parsley Health
- Ro
- RapidSOS
- Sesame
- TytoCare
- Unite Us
- Vault
- Vesta
- VirtualHealth
- Welthy

## Data & Platforms

### ANALYTICS & INSIGHTS
- Aetion
- Alcure
- Clarify
- Covera Health
- H1
- HealthReveai
- Koneksa Health
- Owkin
- Particle Health
- Prognos Health
- TrialSpark
- Verana Health

### PROVIDER ENABLEMENT
- Andros
- BetterPT
- Eligible
- Klara
- MDCalc
- Nomad
- Parachute Health
- Particle Health
- Referwell
- Ribbon
- RubiconMD
- RxHealth
- Stellar Health
- Vercred
- Vytalize
- Wellsheet

### DIAGNOSTICS
- Click Therapeutics
- Ezra
- Imagen
- LetsGetChecked
- OnSight
- Opentrons
- Paige
- Phosphorus
- Pwnhealth
- Somatix
DELOITTE IS PLEASED TO SPONSOR NYCHBL and would like to congratulate these leading 100 digital innovators. Learn more about Deloitte [here](#).

NYC Digital Health 100 Selection Process: To qualify for inclusion, the company must (1) maintain headquarters or major office in New York region and (2) have raised at least a Series A round by 12/31/2020.

<table>
<thead>
<tr>
<th>AbleTo</th>
<th>K Health</th>
<th>Rightway Healthcare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aetion</td>
<td>Kaden Health</td>
<td>Risalto</td>
</tr>
<tr>
<td>AiCure</td>
<td>Kaia Health</td>
<td>Ro</td>
</tr>
<tr>
<td>Alma</td>
<td>Kindbody</td>
<td>RubiconMD</td>
</tr>
<tr>
<td>andros</td>
<td>Klara</td>
<td>Rx.Health</td>
</tr>
<tr>
<td>BetterPT</td>
<td>Koneksa Health</td>
<td>Sesame</td>
</tr>
<tr>
<td>Blink Health</td>
<td>LetsGetChecked</td>
<td>Shine</td>
</tr>
<tr>
<td>Capital Rx</td>
<td>Massive Bio</td>
<td>Simple Health</td>
</tr>
<tr>
<td>Capsule</td>
<td>Maven Clinic</td>
<td>Smart Vision Labs</td>
</tr>
<tr>
<td>Cecilia Health</td>
<td>Medly Pharmacy</td>
<td>Somatix</td>
</tr>
<tr>
<td>Cedar</td>
<td>Monument</td>
<td>Spring Health</td>
</tr>
<tr>
<td>Centivo</td>
<td>Nava</td>
<td>Stellar Health</td>
</tr>
<tr>
<td>Cipher Health</td>
<td>Nomad Health</td>
<td>SWORD Health</td>
</tr>
<tr>
<td>Cityblock Health</td>
<td>Monument</td>
<td>Talkspace</td>
</tr>
<tr>
<td>Clarify Health</td>
<td>Noom</td>
<td>Tempest</td>
</tr>
<tr>
<td>Click Therapeutics</td>
<td>One Drop</td>
<td>Thirty Madison</td>
</tr>
<tr>
<td>Cohero Health</td>
<td>On-Sight Medical</td>
<td>Tia</td>
</tr>
<tr>
<td>Covera Health</td>
<td>Opentrons</td>
<td>TrialSpark</td>
</tr>
<tr>
<td>Cureatr</td>
<td>Oscar Health</td>
<td>Truveris</td>
</tr>
<tr>
<td>DataCubed Health</td>
<td>Owkin</td>
<td>TytoCare</td>
</tr>
<tr>
<td>Eden Health</td>
<td>Pager</td>
<td>Unite Us</td>
</tr>
<tr>
<td>Eligible</td>
<td>Paige</td>
<td>Valera Health</td>
</tr>
<tr>
<td>elovee</td>
<td>Parachute Health</td>
<td>Vault Health</td>
</tr>
<tr>
<td>Extend Fertility</td>
<td>Parsley Health</td>
<td>Verana Health</td>
</tr>
<tr>
<td>Ezra</td>
<td>Particle Health</td>
<td>Vericred</td>
</tr>
<tr>
<td>Force Therapeutics</td>
<td>Phosphorus</td>
<td>Vesta Healthcare</td>
</tr>
<tr>
<td>Fruit Street Health</td>
<td>Prognos</td>
<td>VirtualHealth</td>
</tr>
<tr>
<td>Galileo</td>
<td>PWNHealth</td>
<td>Vyatalize Health</td>
</tr>
<tr>
<td>H1 Insights</td>
<td>Quartet</td>
<td>Wellsheet</td>
</tr>
<tr>
<td>Happify Health</td>
<td>Rapid SOS</td>
<td>Wellth</td>
</tr>
<tr>
<td>Headway</td>
<td>ReferWell</td>
<td>Wethly</td>
</tr>
<tr>
<td>Healthify</td>
<td>Ribbon Health</td>
<td>Zipari</td>
</tr>
</tbody>
</table>

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see [www.deloitte.com/about](http://www.deloitte.com/about) to learn more about our global network of member firms.
What Are Your Super Powers?

Often in healthcare we see start-ups offering a solution in need of a problem. Then there are companies developing products, services and technologies that address real unmet needs. Meet a few New York start-ups striving to make healthcare more accessible, cost-effective and personalized.

TIA IS ARCHITECTING A FUNDAMENTALLY NEW MODEL OF CARE for the most powerful customer in healthcare: women. Our “Medical home” model is both integrated—we fuse gynecology, primary care, mental health, acupuncture into a one-stop-shop—and integrative, considering the diagnosis, treatment and prevention of the female patient through a lifestyle-centric, sex-specific lens.

CAROLYN WITTE
Co-Founder & CEO, Tia

OUR MISSION AT EDEN HEALTH IS TO CREATE A WORLD where every person has a relationship with a trusted healthcare provider. We do this by delivering relationship-based virtual care, seamless patient navigation, comprehensive care coordination, and integration of virtual and in-person care.

MATT MCCAMBRIDGE
Co-Founder & CEO, Eden Health

CENTIVO IS A NEW TYPE OF DIGITAL HEALTH PLAN SOLUTION custom designed for self-funded employers. They’re looking for three key things: sustainable cost-savings, high-quality care for their employees, and a plan that’s easy to use. We’re laser-focused on managing employer costs and offer absolute financial transparency in our fee structure.

ASHOK SUBRAMANIAN
Co-Founder & CEO, Centivo
EVERYTHING WE DO IS BUILT FOR HUMAN FIRST. We use technology and world-leading experts to create experiences and solutions that are tailored to people addressing and managing their health issues. Our platform rivals seeing a specialist in person and encourages patients to stay connected with the same physician to build an ongoing relationship.

STEVEN GUTENTAG
Co-Founder & CEO, Thirty Madison

WE’RE HERE TO SERVE ALL THOSE who seek to build a family. Kindbody provides end-to-end care, from prepartum to return to work, for all. We believe that fertility treatment should be affordable and accessible to all, not just the wealthy few.

GINA BARTASI
Founder & CEO, Kindbody

PROVIDERS HAVE NEVER NEEDED VALUE-BASED CARE MORE. What differentiates Vyitalize is that we don’t silo ourselves, we simply do what is needed to improve health outcomes and lower costs. Our solution combines payer, provider, and digital health, all-in-one because all of these pieces are needed.

FARIS GHAWI
CEO, Vyitalize Health

FULL-BODY MRIS HAVE EXISTED FOR A WHILE, but the cost ranged from $10,000 to $15,000. With Ezra, we brought it down to $2,000 by using software and building AI to make the scans and interpretation faster. We’ve created a way to screen for cancer that’s fast and accurate, but we are still working to make it more affordable. I dream of a future with a $500 full-body scan.

EMI GAL
Co-Founder & CEO, Ezra

WE’RE HERE TO SERVE ALL THOSE who seek to build a family. Kindbody provides end-to-end care, from prepartum to return to work, for all. We believe that fertility treatment should be affordable and accessible to all, not just the wealthy few.

GINA BARTASI
Founder & CEO, Kindbody

PROVIDERS HAVE NEVER NEEDED VALUE-BASED CARE MORE. What differentiates Vyitalize is that we don’t silo ourselves, we simply do what is needed to improve health outcomes and lower costs. Our solution combines payer, provider, and digital health, all-in-one because all of these pieces are needed.

FARIS GHAWI
CEO, Vyitalize Health

FULL-BODY MRIS HAVE EXISTED FOR A WHILE, but the cost ranged from $10,000 to $15,000. With Ezra, we brought it down to $2,000 by using software and building AI to make the scans and interpretation faster. We’ve created a way to screen for cancer that’s fast and accurate, but we are still working to make it more affordable. I dream of a future with a $500 full-body scan.

EMI GAL
Co-Founder & CEO, Ezra

EVERYTHING WE DO IS BUILT FOR HUMAN FIRST. We use technology and world-leading experts to create experiences and solutions that are tailored to people addressing and managing their health issues. Our platform rivals seeing a specialist in person and encourages patients to stay connected with the same physician to build an ongoing relationship.

STEVEN GUTENTAG
Co-Founder & CEO, Thirty Madison

WE’RE HERE TO SERVE ALL THOSE who seek to build a family. Kindbody provides end-to-end care, from prepartum to return to work, for all. We believe that fertility treatment should be affordable and accessible to all, not just the wealthy few.

GINA BARTASI
Founder & CEO, Kindbody

PROVIDERS HAVE NEVER NEEDED VALUE-BASED CARE MORE. What differentiates Vyitalize is that we don’t silo ourselves, we simply do what is needed to improve health outcomes and lower costs. Our solution combines payer, provider, and digital health, all-in-one because all of these pieces are needed.

FARIS GHAWI
CEO, Vyitalize Health

FULL-BODY MRIS HAVE EXISTED FOR A WHILE, but the cost ranged from $10,000 to $15,000. With Ezra, we brought it down to $2,000 by using software and building AI to make the scans and interpretation faster. We’ve created a way to screen for cancer that’s fast and accurate, but we are still working to make it more affordable. I dream of a future with a $500 full-body scan.

EMI GAL
Co-Founder & CEO, Ezra

EVERYTHING WE DO IS BUILT FOR HUMAN FIRST. We use technology and world-leading experts to create experiences and solutions that are tailored to people addressing and managing their health issues. Our platform rivals seeing a specialist in person and encourages patients to stay connected with the same physician to build an ongoing relationship.

STEVEN GUTENTAG
Co-Founder & CEO, Thirty Madison

WE’RE HERE TO SERVE ALL THOSE who seek to build a family. Kindbody provides end-to-end care, from prepartum to return to work, for all. We believe that fertility treatment should be affordable and accessible to all, not just the wealthy few.

GINA BARTASI
Founder & CEO, Kindbody

PROVIDERS HAVE NEVER NEEDED VALUE-BASED CARE MORE. What differentiates Vyitalize is that we don’t silo ourselves, we simply do what is needed to improve health outcomes and lower costs. Our solution combines payer, provider, and digital health, all-in-one because all of these pieces are needed.

FARIS GHAWI
CEO, Vyitalize Health

FULL-BODY MRIS HAVE EXISTED FOR A WHILE, but the cost ranged from $10,000 to $15,000. With Ezra, we brought it down to $2,000 by using software and building AI to make the scans and interpretation faster. We’ve created a way to screen for cancer that’s fast and accurate, but we are still working to make it more affordable. I dream of a future with a $500 full-body scan.

EMI GAL
Co-Founder & CEO, Ezra
Health Equity

The pandemic highlighted the vast health disparities and inequities that exist in the country, particularly for Black and Brown communities. The move to virtual care only exacerbated the problem, because not all people have equal access to broadband and mobile technologies. Healthcare and business leaders in New York are identifying and developing new ways to close these gaps.

Below is an edited portion of an Open Letter written by Gil Addo, CEO of RubiconMD in September 2020. He’s also a member of HT4M (HealthTech4Medicaid) focused on bringing critical new technology to Medicaid enrollees.

Can Telehealth be Saved from Systemic Racism?

Alongside COVID-19, America has been slowly acknowledging the public health crisis of racial injustice. Even prior to COVID, structural racism had a devastating impact on healthcare, education, employment, housing, and infrastructure in Black and Brown communities. Health outcomes have lagged commensurately and dramatically. This is the house that COVID-19 entered. A house poorly equipped, staffed and supported for routine healthcare. Telehealth doesn’t fix the larger problem. Layered on top of our existing inadequate system, telehealth exacerbates the problem. Only investment to combat the underlying system will allow telehealth to reach its true potential of enhanced access to care.

Communities of color and low-income households are frequently confronted by a digital divide with inadequate access to computers, high-bandwidth internet, and remote monitoring devices. While 64% of households with an annual income of $100,000 or greater have access to a smartphone, desktop or laptop computer, broadband internet, and a tablet, only 18% of households making less than $30,000 have the same access.

The solution must then be multipronged. First, there needs to be awareness, understanding and acceptance that systemic racism has massively contributed to the chronic underinvestment in the healthcare system of our communities of color. Second, national and local plans must be developed, tested and scaled to comprehensively address deficiencies and gaps. Finally, investment is necessary to address fundamental gaps in the digital divide and infrastructure to support our community and safety net health system.

Telehealth leaders cannot sit idly by waiting for broad infrastructure changes to come to fruition. As an industry, we must develop programs and services which affirmatively combat structural racism and ensure equitable access.

In hope,

Gil Addo

GIL ADDO
As the pandemic hit, Mount Sinai’s care management teams began receiving calls from the community alerting them to behavioral health issues such as increased suicidality and anxiety. With in-person visits canceled due to COVID, services were being provided virtually. It soon became clear that many of the families lacked broadband access, which prevented them from getting care.

We realized that education had solved that problem earlier in the spring by distributing Wi-Fi-enabled devices, which gave us the idea to piggyback on their infrastructure. We partnered with the Dream School, a public charter school in East Harlem that serves about 1,200 children K-12. We heard from Dream that asthma and behavioral health education were big priorities, so we hosted online forums with primary care doctors and specialists to not only provide education but allow opportunity for families to ask questions directly to the clinicians. We are working on additional projects with the Dream School to empower families to use technology for both medical and social care needs so that they gain confidence in managing their care and the challenges they face every day.

Robert Fields, MD
SVP and Chief Medical Officer of Population Health,
Mount Sinai Health System

Though we needed no reminder, this pandemic continues to show us all that the people who will always suffer the most are communities of color, folks with disabilities, those who are LGBTQIA+, and people with limited economic means. There are 110 million people in the US living in lower-income communities that desperately need better-integrated care. They need a revolution. And they need it now.

Toyin Ajayi, MD
Co-Founder & Chief Health Officer,
Cityblock Health

During COVID, some health plans temporarily began to pay for telehealth visits on par with in-person care, but they only reimbursed video visits, not care via telephone. Many patients we see do not have access to video-enabled devices and can’t use Zoom or Google Hangouts. The notion of only reimbursing video speaks to the underlying socioeconomic issues of access and equity.

Robert Accordino, MD, MSC
Chief Mental Health Officer, Quartet
2020 was the year conversations about depression, anxiety and addiction went mainstream. People across every demographic experienced isolation, loneliness and depression, including children and teens. With one of the highest concentrations of therapists per capita in the country, New York has long been a center of mental health. Now it’s rapidly becoming the epicenter of digital mental health, too. Clinicians and entrepreneurs are introducing new models that address age old problems of access, siloed care and lack of insurance reimbursement.

NEW YORK HAS A RICH AND STORIED TRADITION IN MENTAL HEALTH and psychiatry dating back to Freud’s visit to NYC in 1909. It’s no surprise that as health technology has grown in NYC, an emphasis on mental health start-ups has become evident. I’ve spoken with many founders whose own positive experiences with therapy prompted them to try to use technology to make mental health care more accessible for others.

RAVI N. SHAH, MD, MBA
Founding Director, Columbia Mind Ventures

TIA HAS ALWAYS BELIEVED THAT MENTAL HEALTH IS “CORE” TO WOMEN’S HEALTH and should be integrated into a primary care, medical home model vs. delivered in a silo—both due to the higher rates of anxiety and depression in women, as well as the many female-specific behavioral healthcare challenges like sexual trauma that all too many women experience.

CAROLYN WITTE
Co-Founder & CEO, Tia

PEOPLE ARE GOING TO CONTINUE TO FEEL more comfortable talking about mental health, so we expect to see an ongoing reduction in stigma over time. As the conversation around mental health continues to grow and take shape, we’ll see more organizations looking for solutions that cover the full spectrum of mental health—not just one-size-fits-all solutions.

APRIL KOH
Co-Founder & CEO, Spring Health
WE Grew out of a need for integrated care. Typically, care of the mind and body take place in different offices and different EMR systems. But we know that the best care for patients combines physical and mental health, and we’re solving for that problem by creating care for the whole person, under one virtual roof.

ROBERT ACCORDINO, MD, MSC
Chief Mental Health Officer, Quartet

Our unique ‘reverse’ integrated care model is how SCW supports children and families with complex medical, behavioral, and social needs. By embedding primary care hubs into trusted community-based organizations that offer cross-disciplinary teams of social service and mental health providers, we can deliver care that is holistic, coordinated, and community-engaged.

NICOLE BROWN, MD, MPH
Founder & Chief Health Officer, Strong Children Wellness

Our true innovation lies in our ability to decrease the cost of collaboration between on-campus care settings and our virtual network of providers. Our integrated telemental health programs improve clinical outcomes and reduce time to access care for universities of all sizes.

ED GAUSSEN
CEO, Mantra Health

We’re unique in our use of data and analytics to identify at-risk individuals and align each person’s needs with a highly personalized program. We’ve long believed that it’s important to find the right blend of human and digital care to meet the needs of a complex and heterogeneous group of mental health patients, who may require different interventions. Our longstanding focus on outcomes has enabled us to prove the impact on both physical and behavioral health and overall cost of care.

REENA PANDE, MD
Chief Medical Officer, AbleTo

Our true innovation lies in our ability to decrease the cost of collaboration between on-campus care settings and our virtual network of providers. Our integrated telemental health programs improve clinical outcomes and reduce time to access care for universities of all sizes.

ED GAUSSEN
CEO, Mantra Health

We’re unique in our use of data and analytics to identify at-risk individuals and align each person’s needs with a highly personalized program. We’ve long believed that it’s important to find the right blend of human and digital care to meet the needs of a complex and heterogeneous group of mental health patients, who may require different interventions. Our longstanding focus on outcomes has enabled us to prove the impact on both physical and behavioral health and overall cost of care.

REENA PANDE, MD
Chief Medical Officer, AbleTo
**NEW YORK**

**Mental Health Start-ups to Watch**

With so many start-ups entering the space, it can be confusing to understand the different offerings. While this list is not exhaustive, it represents a good cross-section of the companies within the ecosystem.

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>DESCRIPTION</th>
<th>CUSTOMERS</th>
<th>CONDITIONS</th>
<th>RAISED*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AbleTo</strong></td>
<td>Pioneer in delivering high-quality, outcomes-based mental health care to improve behavioral and physical health and lower medical costs.</td>
<td>Health Plans, Employers</td>
<td>A D S +</td>
<td>$73M</td>
</tr>
<tr>
<td><strong>Alma</strong></td>
<td>Matching platform for mental health providers and patients. Offers administrative and marketing support to providers.</td>
<td>Providers</td>
<td>A D S +</td>
<td>$14M</td>
</tr>
<tr>
<td><strong>happify health</strong></td>
<td>Digital therapeutic platform that empowers users to improve their mental and physical health.</td>
<td>Employers, Health Plans</td>
<td>A D S +</td>
<td>$46M</td>
</tr>
<tr>
<td><strong>Headway</strong></td>
<td>Building national network of therapists who accept insurance.</td>
<td>Health Plans, Providers</td>
<td>A D S +</td>
<td>$32M</td>
</tr>
<tr>
<td><strong>Kaden</strong></td>
<td>Virtual Medication Assisted Treatment (vMAT™) platform provides online visits, group therapy, medication management.</td>
<td>Health Plans, Health Systems</td>
<td>SUD</td>
<td>$19M</td>
</tr>
<tr>
<td><strong>Mantra Health</strong></td>
<td>Telemental healthcare for students, integrating with universities’ existing platform/system.</td>
<td>Universities, Health Plans, Consumers</td>
<td>A D S</td>
<td>$4M</td>
</tr>
<tr>
<td><strong>mindzoom</strong></td>
<td>Platform (technology, content, space) that enables licensed psychiatrists to administer guided ketamine therapy.</td>
<td>Consumers</td>
<td>A D S +</td>
<td>$4M</td>
</tr>
<tr>
<td><strong>mindful</strong></td>
<td>Multiple locations throughout NY for same-day therapy and medication management.</td>
<td>Health Plans, Consumers</td>
<td>A D S +</td>
<td>$1.5M</td>
</tr>
<tr>
<td><strong>monument</strong></td>
<td>Online platform providing affordable medical treatment (therapy, medication) and peer support for alcohol addiction.</td>
<td>Consumers</td>
<td>SUD</td>
<td>$18M</td>
</tr>
<tr>
<td><strong>octave</strong></td>
<td>Virtual and in-person therapy, coaching, support groups, and skills workshops.</td>
<td>Health Plans, Consumers</td>
<td>A D S +</td>
<td>$14.5M</td>
</tr>
<tr>
<td><strong>Ophelia</strong></td>
<td>Online treatment for opioid dependence, based on medication-assisted treatment (MAT).</td>
<td>Consumers</td>
<td>SUD</td>
<td>$3.5M</td>
</tr>
<tr>
<td><strong>proper</strong></td>
<td>Wellness supplements and sleep delivery solutions intended to improve long-term sleep health.</td>
<td>Consumers</td>
<td>1</td>
<td>$9.5M</td>
</tr>
<tr>
<td><strong>Quartet</strong></td>
<td>Platform that makes it easier for people to get the best mental health care for them.</td>
<td>Health Plans, Health Systems</td>
<td>A D S +</td>
<td>$155M</td>
</tr>
<tr>
<td><strong>REAL</strong></td>
<td>Focused on mental wellbeing. Monthly membership includes on-demand therapy pathways, tracking, events and roundtables.</td>
<td>Consumers</td>
<td>A S</td>
<td>$6M</td>
</tr>
<tr>
<td><strong>spring health</strong></td>
<td>Mental health benefits platform for employers. Precision Mental Healthcare model matches employee with care and dedicated Care Navigator.</td>
<td>Employers</td>
<td>A D S +</td>
<td>$106M</td>
</tr>
<tr>
<td><strong>talk space</strong></td>
<td>Online therapy and psychiatric treatment through its network of licensed therapists and prescribers.</td>
<td>Consumers, Employers, Health Plans</td>
<td>A D S +</td>
<td>$410M</td>
</tr>
<tr>
<td><strong>TEMPEST</strong></td>
<td>Personalized recovery plans for alcohol addiction. Provides education, support, and community via membership model.</td>
<td>Consumers</td>
<td>AUD</td>
<td>$14M</td>
</tr>
<tr>
<td><strong>ValieraHealth</strong></td>
<td>Telemental health offering team-based care for coaching and therapy, medication management and psychiatry.</td>
<td>Employers, Health Systems, Health Plans</td>
<td>A D S +</td>
<td>$11.5M</td>
</tr>
</tbody>
</table>

**CONDITIONS KEY**

- A: Anxiety
- D: Depression
- S: Stress
- +: Multiple Conditions
- AUD: Alcohol Use Disorder
- SUD: Substance Use Disorder
- I: Insomnia

* Based on Pitchbook data through 1/31/21.
HEALTHCARE REGULATORY

What’s in Store For 2021?

In 2020, swift regulatory changes helped make widespread adoption of telehealth and virtual care possible. We sat down with Alexis Gilroy and Maureen Bennett, two legal experts at Jones Day, to discuss the future regulatory landscape for these technologies in both care delivery and clinical trials. For ongoing regulatory insights and tracking, subscribe to Vital Signs, a quarterly publication tracking the latest must-know information.

Q What are you expecting this year on telemedicine legal and regulatory change?

A In the federal sphere, it is all about reimbursement. Although we have been operating during the public health emergency under very helpful waivers that significantly expanded telemedicine coverage to Medicare beneficiaries, post-emergency federal legislation will be necessary to remove decades-old statutory limitations that narrowed Medicare telehealth to patients at certain facilities in rural areas. Given recent policy activity and Congressional hearings, stakeholders believe some permanent legislative change on Medicare coverage is possible in 2021. As to states (those with the primary legal authority over health provider regulation and thus telemedicine), the annual legislative cycle kicked-off with a running start on various telemedicine related topics – from telehealth modality (e.g., video, audio-only, async) changes proposed by some states to a focus on Medicaid coverage of telehealth and cross-state licensure in others. So, buckle-up, we are in for lots of telehealth policy in 2021!

Q Are you seeing expanded applications for the use of telemedicine modalities beyond clinical care?

A Yes, indeed! In recent years, industry stakeholders have increasingly pursued a range of “decentralized”, “remote” or “virtual” clinical trial protocols, which involve the leveraging of wearables and other remote data gathering and communication technologies, together with the deployment of home health personnel to perform certain at home trial procedures. These developments implicate both FDA and state regulation for US state trials, and there has been broad acknowledgment that further regulatory clarity is needed going forward. In that regard, the onset of COVID in 2020 did provide impetus for FDA to issue guidance on the conduct of trials remotely from traditional “brick and mortar” sites. FDA’s guidance provided numerous recommendations for sponsors, investigators and IRBs to consider for adapting ongoing trials or when preparing for the launch of a new trial, during the COVID-19 public health emergency, with subject safety and data integrity being paramount considerations. Among many other issues, FDA addresses the potential use of telemedicine modalities for remote trial visits. Other international regulatory authorities, including the EMA and MHRA, also have issued guidance for the conduct of clinical trials during the COVID-19 pandemic. Although certain COVID-19 related guidance may expire at the end of the public health emergency, some may be extended in one form or another. There is increasing enthusiasm for the flexibility and efficiencies associated with home clinical trial procedures, where appropriate. For example, elderly or physically challenged subjects and their caregivers may appreciate the option to participate in clinical trials from home and communicating with the study doctor through videoconference. Telemedicine can also move forward other important objectives, including increasing the diversity of clinical trial participants to achieve greater equity in health outcomes.
New York once again proved its position as leader in therapeutics when Pfizer became the first company to emerge with a vaccine for COVID-19. But smaller NYC biotechs made equally important contributions. Some leveraged their experience and pivoted to provide immediate solutions such as face masks and at-home testing. Others stayed focused on their core businesses and found ways to adapt to the new remote reality. Prevail Therapeutics ended the year with a great exit: $1B sale to Lilly. Several companies went public, some through traditional IPO like Schrodinger, Zentalis and Delcath Systems, others through a SPAC merger like Nuvation Bio and 180 Life Sciences.

“BIOTECH COMPANIES LIKE OURS REQUIRE PHYSICAL LABS TO GENERATE REVENUE, but we learned that there were many ways to keep our employees productive during the lockdown. For instance, we began digging deeper into our datasets and research syntheses, by which we were able to improve our efficiency. We'll continue to do so post-COVID.”

MISTI USHIO, PHD
CEO, TARA Biosystems

“IN THE WAKE OF THE PANDEMIC, NEW YORK opened its arms to partner with nimble companies that generated everything from masks to diagnostic tests and even therapeutics. This agile mindset will accelerate NY’s attractiveness as a premier hub for incubating and launching biotech companies for years to come.”

STACEY SELTZER
Partner, Aisling Capital

“WE LOOK SPECIFICALLY AT CONSTITUTIONAL GENETICS—WHAT MAKES UP YOUR DNA—the genes you inherited from your parents. In most specialties, physicians typically do not order a genetic test until you’re very sick due to lack of insurance coverage for preventive screening. While many conditions are avoidable, they’re generally not discovered until there’s been an event. Our goal is to change the care paradigm so that we screen everyone before there’s a problem.”

ALEXANDER BISIGNANO
Co-Founder & CEO, Phosphorus
THE RESPONSE TO COVID ACROSS NEW YORK WAS AMAZING IN NEARLY EVERY RESPECT. Among the big successes in diagnostics are New York companies like Mirimus and DETECT by Homodeus, both of which are operating at the forefront of test development; and Sema4 and the New York Genome Center, which are playing active roles in both the discovery of genomic variants and keeping the scientific community current on advancements in the field from across the globe.

JENNIFER HAWKS BLAND
CEO, NewYorkBIO

THE SUCCESS WITH DEVELOPMENT OF THE CORONAVIRUS VACCINES has been simply remarkable. It’s brought both a reputational boost, and a boost in overall investments, and it has made it easier for small companies like ours to raise the capital needed to continue innovating.

MATTHEW PRICE
Co-Founder & COO, Phosplatin Therapeutics

MANY SMALLER NY-BASED COMPANIES QUICKLY REDEPLOYED THEIR ASSETS and operations to address immediate needs during the global pandemic. Shapeways in Long Island City began 3D printing face shields, a team from New Lab in Brooklyn developed a low-cost bridge ventilator and Opentrons was selected to run the Pandemic Response Lab, dedicated to processing COVID-19 tests, at the Alexandria Center.

MARIA GOTSCH
President & CEO, Partnership Fund for New York City

“...
Healthcare SPACs

Special purchase acquisition companies (SPACs) exploded in popularity across all industries in 2020, and healthcare was no exception. SPACs are an alternative to a traditional IPO in which a blank-check company (i.e. SPAC) merges with a private business to form a publicly-traded entity. New York investors were part of this trend: investment banks, hedge funds, private equity and venture capital firms all created SPACs during the year.

A significant transaction that helped catalyze the popularity of healthcare SPACs occurred in 2019, when New York-based Immunovant merged with Health Sciences Acquisition Corp. Since its IPO, Immunovant has been one of the top performers on the NASDAQ, delivering 4x returns to investors.

There are both advantages and drawbacks of SPACs relative to traditional IPOs. We spoke with three investors to learn more about when and how SPACs work for emerging healthcare companies.

**JONAS GROSSMAN**
President, Chardan

**Why have SPACs become so popular?**

We’ve always been big believers in SPACs because you can use them as a tool to bring companies public earlier. SPACs allow you to marry due diligence without a crossover round before the IPO, leading to less dilution for private companies. In early 2020, I predicted there would be six biotech SPACs, and people thought I was crazy. Now as of year-end, there are 34 healthcare-focused SPACs seeking targets, 19 of those are biotech specific, four have announced transactions, and six have closed.

**And healthcare SPACs?**

Historically, SPACs were not focused on healthcare, aside from a handful of healthcare services. An easy-to-understand business is usually the best opportunity for SPACs—traditionally that’s meant consumer goods and industrials. Now there’s an appetite for growth stories, so biotech SPACs have taken off. In particular, the Health Sciences Acquisition Corp/Immunovant (IMVT) deal woke people up—they started to realize the potential in biotech. Now, lots of SPACs are looking at digital health and healthcare IT as well, and I expect that to continue going forward.

**What’s one thing we should know about Chardan?**

Chardan has established a reputation for "financing the frontier of healthcare" by focusing on industry disruption and innovation. Seventy percent of our focus is on disruptive biotech sectors like genetic medicines, cell therapy, and microbiome medicines. We also see potential in devices, diagnostics, digital health, and other burgeoning areas—we’re always looking for growth companies with technology or an asset that have the potential to generate 5-10x investment returns, by creating and sharing in real value for society.

**RAJIV SHUKLA**
Chairman & CEO, Alpha Healthcare Acquisition Corp.

**What are the advantages of taking a company public via a SPAC?**

SPACs are ideally suited for high-growth companies where it is important to be able to provide growth forecasts which is not permitted in regular IPOs. The SPAC process permits a target company to firm up financing before a public announcement. Whereas in an IPO, on account of having to file terms publicly before book building, targets are either over-conservative in valuing themselves or forced to publicly accept a diminution in terms or, worse, shelve the IPO after conducting a public process. One can put together incentive structures linked with future growth which is not possible in an IPO.
Which areas of healthcare are most attractive for SPACs?

Sectors where one is (a) experiencing substantial disruptive growth i.e. the investment thesis is future-oriented thus more time is needed for diligence (b) where there is appreciable public/private arbitrage (c) there are large private companies with limited IPO windows—in the past, device and diagnostic companies have fit the bill.

What is your experience with SPACs?

We closed a merger with DermTech (DMTK), a molecular cancer diagnostics company in 2019 which is trading at 11x the transaction price as of early February. We recently announced a $1.1 billion merger with Humacyte, a universally implantable human tissue regenerative medicine company which has attracted significant support from marquee investors.

Why did you create Lux Health Tech Acquisition Corp?

We felt the SPAC was a really good way to disrupt healthcare and technology. Our thesis is that a funding gap exists across healthcare technology which impacts devices, digital health, lab equipment, diagnostics and telehealth. Biotech is less of a focus because many other SPACs are in that sector. In health tech, many start-ups become tuck-in acquisitions to the incumbent companies, leaving a lot of opportunity on the table. These start-ups develop their first application but don’t have the capital to propel the business further. That’s where we come in.

Why a SPAC vs. traditional IPO?

For the right company, SPACs provide critical benefits. Fundraising is treated more similar to a private raise than public company offering. The investors are all having conversations about the company’s direction, which creates more alignment. We think the SPAC is a wonderful opportunity to provide curated go-public experiences.

“My thesis is that a funding gap exists across healthcare technology which impacts devices, digital health, lab equipment, diagnostics and telehealth.”

JOSH DEFONZO CEO, Lux Health Tech Acquisition Corp.

A FEW RECENT EXAMPLES OF REVERSE MERGERS IN THE NEW YORK AREA:

**Clover Health**

Merged with Social Capital Hedosophia Holdings Corp in $7.3B deal

**Nuvation Bio**

Merged with Panacea Acquisition in $1.3B deal

**180° Life Sciences**

Merged with KBL Merger Corp in $175M deal

**MultiPlan.**

Merged with Churchill Capital Corp III in $11B deal
Where Will the Money Flow Next?

It’s been said healthcare transformed more in five months during COVID than it has in the past 10 years. Now that the wheels are turning, and money is flowing, where will we see new investment? What trends are on the horizon? These leaders offer a look ahead.

**The Spend on Musculoskeletal (MSK) Alone** is approximately $200 billion in the US and most of that care is delivered in person. The nuance on how care is delivered in certain verticals (like MSK for example) will require platforms to be built for specific use cases. As a significant amount of care migrates from in person to virtual, there will be enormous potential to create expansive vertical-specific platforms.

**Ryan Darnell**  
Managing Partner, Max Ventures

**In 2021 We Expect to See the Practice of Medicine Evolve** more to precision medicine, enabled by the widespread availability of molecular diagnostics. Key drivers include increased access to and declining cost of gene sequencing; new drug discoveries, and real-world data on biomarkers that help match patients to the best therapies.

**Charles Boorady**  
Managing Partner, Health Catalyst Capital

**The Market Will Increasingly Favor Telemedicine Models** that offer full-stack digital services, including different modalities of care, integrative and longitudinal care, those focused on specific verticals and life phases (like menopause!) and chronic conditions.

**Jannine Versi**  
Co-Founder & COO, Elektra Health

**One of the Mega-Trends We’ve Seen Over the Past 5-7 Years** is the rise of direct-to-consumer healthcare. High-deductible plans are increasing, so people are paying more out of pocket. As a result, they are taking more control over their health, looking at what they’re spending and why. COVID only accelerated this trend.

**Rick Heitzmann**  
Partner, FirstMark Capital
THERE’S BEEN A SURGE IN DEMAND FOR MENTAL HEALTH SUPPORT as a result of COVID-19 and the events of 2020. The continued growth and popularity of digital solutions will be a major trend, as more and more organizations and individuals look for solutions that are both effective and easy to access.

APRIL KOH
Co-Founder & CEO, Spring Health

FIVE YEARS FROM NOW I HOPE TO SEE ON-DEMAND, PRECISION INSIGHTS as ubiquitous in healthcare as the Bloomberg Terminal is in banking. In 2021, we’ll see more organizations switch off traditional, manual analytics reporting and move to highly automated platforms that deliver precise, micro-level insights at lightning-fast speed.

JEAN DROUIN, MD
CEO, Clarify Health

WE’RE LOOKING INTO THE CONFLUENCE OF WOMEN’S HEALTH AND AGING. Menopause is a $600 billion marketplace. A lot of women have been silently suffering, and we’re being thoughtful about the problems and solutions for our aging population.

ADRIANNA SAMANIEGO
Investor, Female Founders Fund
On the Frontlines

In December, NYCHBL hosted Healthcare Rocks!, a virtual concert honoring the heroes of 2020. It was a magical night that included candid conversations with clinicians who were on the frontlines battling COVID-19. We’ve captured their reflections below and added several more. Their strength, compassion and hope will inspire you.

“WHAT STOOD OUT THE MOST WAS THE PANDEMIC of racism that came out of this pandemic. Disproportionately, Black and Brown people have died from the pandemic, not because of the virus itself, more because of systematic racism. I work in a very poor community—a level 1 trauma center in Brooklyn—and there are many institutional disparities. Until we have these painful conversations that racism is a public health issue, we’re not going to move past this level of uncertainty.

ARABIA MOLLETTE, MD
Emergency Medicine Physician, Brookdale University Hospital

“WHEN THE PANDEMIC HIT IN MARCH, Mount Sinai was one of the first hospitals to jump into action, and many medical students joined in to help. We organized one of the largest medical school responses in the country in close partnership with our hospital system, helping with everything from coordinating PPE donations, triaging telehealth visits to staffing pharmacy sites and boosting our COVID-19 testing capabilities.

SHERMAN LEUNG
Medical Student, Icahn School of Medicine at Mount Sinai and Associate, AlleyCorp

“AFTER 35 YEARS IN PRIVATE PRACTICE, I arrived as a volunteer at Bellevue in April 2020. Being resolute in my desire to do everything for each patient, I mustered my energy to move the COVID-19 mountain. However, the virus was solid, alien, unforgiving, and so deadly. For each patient, I felt immeasurable sadness that I couldn’t do more. I spent time with families hoping to be of comfort. It reminded me that empathy, humility, and kindness are vital in the care of each patient, especially when we do not have a cure.

ANNETTE OSHER, MD
Cardiologist

“SERVING AS A FRONTLINE HCW during the first wave of the pandemic was a surreal experience. I held patients’ hands while increasing their oxygen, helped them FaceTime with their families when visitors weren’t allowed in, and provided rehab to patients as they took their first steps after being on a ventilator for weeks. We were driven by pure adrenaline to save lives during the NYC surge.

SARAH URKE, PT
Acute Care Physical Therapist, NewYork-Presbyterian
IN MARCH, I WAS DEPLOYED IMMEDIATELY to Elmhurst, a city hospital, that operates on a shoestring budget and is always at maximum capacity. Having hundreds of COVID patients per day flooding into the ER completely overwhelmed their system. Elmhurst became the epicenter of the epicenter… While we saw a lot of suffering, we also witnessed some incredible human resilience. Everybody in the hospital pulled together with heroic effort, from the attendings in their sixties and seventies, to med students and nurses, right down to the cafeteria workers and janitors who didn’t miss a beat.

BEN GOLD, MD
Cardiology Fellow,
Mount Sinai Health System

ONE OF THE FLOORS OF THE CHILDREN’S HOSPITAL was converted for adults, to take care of coronavirus patients. Many of us hadn’t taken care of adult patients in close to a decade, so we had to relearn adult medicine. It was certainly a trying time with more patient death than many of us have seen in our careers. But there was also so much humanity that came into it. You saved patients, comforted patients, and said goodbye to patients when you needed to. We had the best of outcomes and the worst of outcomes, and you had to deal with that as a physician.

RAY LORENZONI, MD
Fellow, Pediatric Cardiology,
Children’s Hospital at Montefiore

SINCE THE PANDEMIC STARTED my role as a nurse has changed. We now wear an invisible cape. Many see us as heroes, but we are doing the work we are trained to do—taking care of people and saving lives. We saw the Navajo come together to help protect elders and those most vulnerable to COVID-19, as well as bring food, water, and supplies to those in need. The courage and resiliency of the workers on the frontlines when the pandemic hit were a beacon of hope for what was to come.

VIOLETA MICHEL, RN
Pediatric Nurse, Navajo Nation, Indian Health Service in Shiprock, NM (raised in Manhattan)

VOLUNTEERING AT THE BEGINNING OF THE PANDEMIC, WE WORKED SIDE BY SIDE IN THE ICU. We met health care providers from around the country who came to NYC to fight this disease we knew so little about. We pooled our common knowledge and learned medicine in real time. We grieved each other’s losses and celebrated all the victories… including getting married in late 2020!

ROSHINI MALANEY, DO
Cardiologist, Staten Island University Hospital, Northwell Health

VIRAL PATEL, MD
Founder and CEO, Radish Health
BY FAR THE BIGGEST LEARNING is that the success of any start-up lies within the quality of the team. An A+ team will build an A+ product; a B team will build a mediocre product.

EMI GAL
Co-Founder & CEO, Ezra

THE MOST IMPORTANT THING TO UNDERSTAND IN THE U.S. HEALTHCARE SYSTEM is "Who pays?" and "Who are you providing value to?" Often those are different entities. If you conflate the two, it's difficult to be successful, so it's necessary to find approaches that begin to merge those two interests.

MATT MCCAMBRIDGE
Co-Founder & CEO, Eden Health

IN 2020 WE SAW OUR NOTORIOUSLY CONSERVATIVE INDUSTRY ADOPT TECHNOLOGY AND ANALYTICS with unprecedented speed. In record time, providers switched to televisits, health plans remodeled their forecasts, and pharma companies developed vaccines. It makes me hopeful that we have reset the trajectory of innovation and adoption of technology and analytics in healthcare for good.

JEAN DROUIN, MD
CEO, Clarify Health

OVER $250 BILLION OF ANNUAL HEALTH CARE DELIVERY is going to be shifted from in-person to online soon. The underlying APIs and technologies needed to accelerate digital adoption and support the new virtual healthcare ecosystem represent high-return opportunities for both entrepreneurs and investors.

RYAN DARNELL
Managing Partner, Max Ventures

WE'VE ALWAYS HAD AN EMPHASIS ON CULTURE—our guiding principles are embedded throughout the company. We've been a sourcing and staffing machine from day one. In 2020, we had over 13,000 applicants and hired 119 people, less than 1%. My belief is that you never compromise on hiring.

MARK NATHAN
Founder & CEO, Zipari

WE ARE ON A MISSION TO DEMOCRATIZE WOMEN'S HEALTH. Everything we do is driven by giving women access to care. There's so much talk about access, but not a lot of follow up. One of the key things I've told my team, "Let's stop talking about it and let's just start doing it.

CARRIE SIUBUTT
CEO, Simple Health
SURVEY METHODOLOGY

Data used in the creation of this report was obtained from a variety of sources including but not limited to company press releases, EDGAR filings, Crunchbase, Pitchbook, CB Insights and covered the period from 01/01/2020 to 12/31/2020. A company was included if it (1) listed New York City as its corporate headquarters or a major office (2) the company received seed, angel, early-stage or late-stage funding of at least $1M during the period 01/01/2020 to 12/31/2020. Deal date was used to determine placement in 2020. Companies that won grant funding, prize money or acceptance into accelerators/incubators were not included in the analysis nor companies that received less than $1M in total funding.

DISCLAIMER

This report is provided for informational purposes only. Where possible, we verified information obtained through publicly-available sources (e.g. company press releases, news reports). If you find an error in the report, please contact us at info@nychbl.com so that we can correct it.